MDM2 is a Promising Synthetic Lethal Candidate for ARID1A‐Mutated Ovarian Clear Cell Carcinoma DOI Open Access
Tomoka Maehana, Naoki Kawahara,

Kyohei Nishikawa

и другие.

Опубликована: Окт. 14, 2024

Background: Ovarian clear cell carcinoma (OCCC) is a type of ovarian cancer with poor prognosis if detected in the progressive stage since there less effective chemotherapy. Recent advancements molecular-targeted drugs have not substantially affected OCCC treatment. Therefore, we explored potential targeting MDM2 cells. Methods: We used TOV-21G and KOC7c cells as ARID1A mutant-type, RMG-I ES2 wild-type. Then, performed small interfering library screening, Western blotting, real-time polymerase chain reaction analysis, proliferation assay, cycle time-lapse assessment, DNA damage assessment. Next, to generate murine intraperitoneal tumors, 7.5 × 106 200 μL phosphate-buffered saline were injected subcutaneously into intraperitoneum 5–6-week-old athymic nude mice. Results: Using various lines mutations or without mutation, results showed that interference effectively reduced ARID1A-mutant but wild-type Additionally, against wild strains reproduced susceptibility interference. In vivo experiments demonstrated nutlin-3, an inhibitor, significantly suppressed tumor growth mouse model. Conclusion: These findings suggest may be viable strategy for treat-ment ARID1A-mutated OCCC, offering new therapeutic approach this challenging cancer.

Язык: Английский

Endometriosis and endometriosis-associated ovarian cancer, possible connection and early diagnosis by evaluation of plasma microRNAs DOI
Pierluigi Giampaolino, Michela Dell’Aquila, Pierlorenzo Pallante

и другие.

ONCOLOGIE, Год журнала: 2025, Номер unknown

Опубликована: Апрель 4, 2025

Язык: Английский

Процитировано

0
Association between gynecologic cancer and Alzheimer’s disease: a bidirectional mendelian randomization study DOI Creative Commons
Di Cao, Shaobo Zhang, Yini Zhang

и другие.

BMC Cancer, Год журнала: 2024, Номер 24(1)

Опубликована: Авг. 21, 2024

Alzheimer's disease (AD) manifests with a higher rate of occurrence in women. Previous epidemiological studies have suggested potential association between AD and gynecological cancers, but the causal relationship them remains unclear. This study aims to explore link 12 types cancers using bidirectional Mendelian randomization (MR) approach. We obtained genetic correlation tools for data from most extensive genome-wide study. Genetic were also sourced Finnish Biobank. These include breast cancer (BC), cervical adenocarcinoma (CA), squamous cell carcinoma (CSCC), (CC), endometrial (EC), ovarian endometrioid (OEC), (OC), serous (OSC), situ (BCIS), (CCIS), (ECIS), vulvar (VCIS). used inverse-variance weighted (IVW) model analysis conducted horizontal pleiotropy tests, heterogeneity MR-PRESSO leave-one-out analyses ensure robustness our results. applied replication meta-analysis further validate experimental The found that EC (P_IVW =0.037, OR [95% CI] = 1.032 [1.002, 1.064]) CCIS 0.046, [1.011, increase risk AD, whereas OC was negatively correlated 0.016, 0.974[0.954, 0.995]). In reverse MR analysis, increased CC 0.039, 1.395 [1.017, 1.914]) VCIS 0.041, 1.761 [1.027, 2.021]), OEC 0.034, 0.634 [0.417, 0.966]). Sensitivity results demonstrated robustness. findings substantiated through meta-analyses. Our supports cancers. encourages research into incidence female patients active prevention AD.

Язык: Английский

Процитировано

0
MDM2 is a Promising Synthetic Lethal Candidate for ARID1A‐Mutated Ovarian Clear Cell Carcinoma DOI Open Access
Tomoka Maehana, Naoki Kawahara,

Kyohei Nishikawa

и другие.

Опубликована: Окт. 14, 2024

Background: Ovarian clear cell carcinoma (OCCC) is a type of ovarian cancer with poor prognosis if detected in the progressive stage since there less effective chemotherapy. Recent advancements molecular-targeted drugs have not substantially affected OCCC treatment. Therefore, we explored potential targeting MDM2 cells. Methods: We used TOV-21G and KOC7c cells as ARID1A mutant-type, RMG-I ES2 wild-type. Then, performed small interfering library screening, Western blotting, real-time polymerase chain reaction analysis, proliferation assay, cycle time-lapse assessment, DNA damage assessment. Next, to generate murine intraperitoneal tumors, 7.5 × 106 200 μL phosphate-buffered saline were injected subcutaneously into intraperitoneum 5–6-week-old athymic nude mice. Results: Using various lines mutations or without mutation, results showed that interference effectively reduced ARID1A-mutant but wild-type Additionally, against wild strains reproduced susceptibility interference. In vivo experiments demonstrated nutlin-3, an inhibitor, significantly suppressed tumor growth mouse model. Conclusion: These findings suggest may be viable strategy for treat-ment ARID1A-mutated OCCC, offering new therapeutic approach this challenging cancer.

Язык: Английский

Процитировано

0